Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA® (pemetrexed) and CYRAMZA® (ramucirumab) with Merck's KEYTRUDA® (pembrolizumab) Show Encouraging Results in Non-Small Cell Lung Cancer (NYSE:LLY)

Patients Receiving ALIMTA-KEYTRUDA-Carboplatin Combination Demonstrate Response Rate of 71 Percent
Majority of NSCLC Patients Receiving CYRAMZA-KEYTRUDA Combination Experience Decrease in Target Lesions
Responses Observed Regardless of PD-L1 Expression

Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA® (pemetrexed) and CYRAMZA® (ramucirumab) with Merck's KEYTRUDA® (pembrolizumab) Show Encouraging Results in Non-Small Cell Lung Cancer (NYSE:LLY)